Zevra Therapeutics Inc.
$ 8.93
-0.45%
25 Feb - close price
- Market Cap 502,737,000 USD
- Current Price $ 8.93
- High / Low $ 9.23 / 8.88
- Stock P/E 19.00
- Book Value 2.37
- EPS 0.47
- Next Earning Report 2026-03-10
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.08 %
- ROE 0.35 %
- 52 Week High 13.16
- 52 Week Low 6.19
About
Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company is headquartered in Celebration, Florida.
Analyst Target Price
$22.54
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-12 | 2025-05-05 | 2025-03-26 | 2024-11-12 | 2024-08-13 | 2024-05-08 | 2024-03-05 | 2023-11-07 | 2023-08-14 | 2023-05-15 | 2023-03-07 |
| Reported EPS | -0.01 | -0.06 | -0.06 | -0.69 | -0.69 | -0.48 | -0.4 | -0.4 | -0.4 | -0.15 | -0.34 | -0.26 |
| Estimated EPS | -0.03 | 2.19 | -0.1814 | -0.3986 | -0.42 | -0.43 | -0.48 | -0.27 | -0.3 | -0.34 | -0.23 | -0.17 |
| Surprise | 0.02 | -2.25 | 0.1214 | -0.2914 | -0.27 | -0.05 | 0.08 | -0.13 | -0.1 | 0.19 | -0.11 | -0.09 |
| Surprise Percentage | 66.6667% | -102.7397% | 66.9239% | -73.1059% | -64.2857% | -11.6279% | 16.6667% | -48.1481% | -33.3333% | 55.8824% | -47.8261% | -52.9412% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-10 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.05 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ZVRA
2026-02-19 15:27:56
Johnson Fistel, PLLP is investigating potential claims on behalf of investors in Zevra Therapeutics, Inc. (ZVRA) following significant stock price declines. The investigation focuses on whether Zevra's executive officers complied with federal securities laws after an $11.7 million inventory write-down and the resignation of its CFO led to investor losses. Shareholders who purchased Zevra securities and suffered losses are encouraged to contact Johnson Fistel for more information.
2026-02-19 09:08:00
The article provides a detailed analysis of Zevra Therapeutics Inc. (NASDAQ: ZVRA), highlighting its near-term positive sentiment, mid-term weak bias, and long-term strength. It outlines various AI-generated institutional trading strategies including position trading, momentum breakout, and risk hedging, along with specific entry points, targets, and stop losses. The analysis also includes multi-timeframe signal analysis, identifying support and resistance levels for different horizons.
2026-02-18 18:28:10
Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Zevra Therapeutics, Inc. (NASDAQ: ZVRA) following significant stock price declines. The investigation focuses on Zevra’s executive officers and whether investor losses can be recovered under federal securities laws. Shareholders who suffered losses are encouraged to contact Johnson Fistel for more information.
2026-02-09 21:59:02
Zevra Therapeutics participated in the Nasdaq opening bell ceremony, marking a significant achievement for the company. This event highlights Zevra Therapeutics' commitment to operational progress and market presence. Nasdaq opening bell ceremonies typically recognize organizations with notable accomplishments or milestones within the financial community.
2026-02-08 08:00:00
This article analyzes Zevra Therapeutics Inc. (NASDAQ: ZVRA), highlighting a weak near-term sentiment but strong long-term potential, characterized by a mid-channel oscillation pattern. It presents three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, showing varying support and resistance levels across different time horizons. The report suggests potential choppiness due to divergent sentiments and offers institutional-grade analysis for subscribers.
2026-02-06 21:58:04
Zevra Therapeutics unveiled encouraging new real-world data at the 22nd Annual WORLDSymposium™ regarding its drug MIPLYFFA® (arimoclomol) for Niemann-Pick Disease Type C (NPC). The data, spanning up to four years, indicate that MIPLYFFA is well-tolerated and effectively stabilizes disease progression in both pediatric and adult NPC patients. Notably, a post-hoc analysis of the NPC002 trial showed a statistically significant slowing of disease progression when MIPLYFFA was combined with miglustat, with benefits observed as early as three months into treatment.
